https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/347 2026-07-24T15:09:45Z 2026-07-24T15:09:45Z 조정기 https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/219466 2026-07-23T07:32:56Z 2026-05-17T00:00:00Z

Title: Public Urologic Ultrasound Open Datasets and Recent Evidence on AI-based Hydronephrosis Detection and Tissue Harmonic Imaging Performance: A Structured Evidence Summary Authors: 조정기

2026-05-17T00:00:00Z 조정기 https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/219461 2026-07-23T07:32:05Z 2026-05-17T00:00:00Z

Title: Artificial Intelligence Performance in Urological Ultrasound: Systematic Evidence Summary and Meta-analytic Synthesis Using Open Data and Publicly Available Results Authors: 조정기

2026-05-17T00:00:00Z Kim, Woo-Joong Lee, Hye-Soon Bang, So-Young Bin Joo, Young Kang, Bo-Kyeong Kim, Mimi Kim, Hyunsung Park, Sung Yul Park, Woong-Yang Shin, Eui-Cheol Bae, Sang-Cheol https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/213857 2026-06-22T01:00:37Z 2026-04-01T00:00:00Z

Title: Treatment nonresponders in lupus nephritis characteristically exhibit persistent type I interferon signalling in monocytes: a longitudinal single-cell transcriptomic analysis Authors: Kim, Woo-Joong; Lee, Hye-Soon; Bang, So-Young; Bin Joo, Young; Kang, Bo-Kyeong; Kim, Mimi; Kim, Hyunsung; Park, Sung Yul; Park, Woong-Yang; Shin, Eui-Cheol; Bae, Sang-Cheol Abstract: Objectives: We aimed to characterise the dynamic transcriptional changes associated with treatment responses in lupus nephritis (LN) through longitudinal single-cell RNA sequencing analysis of peripheral blood mononuclear cells (PBMCs) during standard-of-care induction therapy. Methods: We leveraged the Korean Unlimited multi-Dimensional Omics research in Systemic lupus erythematosus cohort, comprising patients with biopsy-proven active proliferative LN. Single-cell RNA sequencing of PBMCs was conducted at baseline and subsequently at 3, 6, and 12 months following initiation of therapy (n = 10). For validation purposes, bulk RNA sequencing of monocytes was performed in an independent patient group at baseline and at 3 months (n = 13). Renal response was classified as complete response or nonresponse at 12 months according to predefined criteria. Results: In single-cell RNA sequencing analysis of patients with LN, the myeloid cell population—particularly classical and intermediate monocytes—demonstrated the highest number of differentially expressed genes following induction therapy. Weighted gene coexpression network analysis identified distinct gene modules closely associated with treatment responses. Complete responders exhibited progressive suppression of type I interferon (IFN-I) signalling, whereas nonresponders maintained persistent IFN-I-driven gene expression characterised by sustained inflammatory features. Bulk RNA sequencing of monocytes from an independent group of patients with LN confirmed that 6 IFN-I-responsive genes (IRF7, ISG15, LY6E, IFI44, IFI44L, and IFI6) were significantly downregulated by 3 months in complete responders, but not in nonresponders. This gene signature correlated with both proteinuria and disease activity scores. Conclusions: This study demonstrates that persistent IFN-I-driven gene expression in monocytes characterises treatment resistance in LN. Our findings suggest that early transcriptional profiling may enable timely identification of nonresponders and warrant further investigation in larger, independent cohorts.

2026-04-01T00:00:00Z Lee, Seung Wook Lee, Seung Hwan Kim, Jae Heon Noh, Joon Hwa Lee, Jun Ho Ha, U-syn Oh, Cheol Young Kang, Taek Won Lee, Gyeongseop Lee, Sangchul Han, Deok Hyun Han, Jun Hyun Song, Sang Hoon Park, Hyun Jun Chung, Byung Ha Min, Gyeong Eun Jeong, In Gab Moon, Kyung Hyun Kim, Won Tae Lee, Ji Youl Kim, Choung-soo https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/219623 2026-07-24T03:00:14Z 2026-04-01T00:00:00Z

Title: Combined therapy with dutasteride and tadalafil vs dutasteride or tadalafil monotherapy in benign prostatic hyperplasia: a randomised phase III trial Authors: Lee, Seung Wook; Lee, Seung Hwan; Kim, Jae Heon; Noh, Joon Hwa; Lee, Jun Ho; Ha, U-syn; Oh, Cheol Young; Kang, Taek Won; Lee, Gyeongseop; Lee, Sangchul; Han, Deok Hyun; Han, Jun Hyun; Song, Sang Hoon; Park, Hyun Jun; Chung, Byung Ha; Min, Gyeong Eun; Jeong, In Gab; Moon, Kyung Hyun; Kim, Won Tae; Lee, Ji Youl; Kim, Choung-soo Abstract: Objectives To evaluate the efficacy and safety of a fixed-dose combination (FDC) of dutasteride and tadalafil vs monotherapy in patients with benign prostatic hyperplasia (BPH). Patients and Methods This phase III trial enrolled 667 patients. After screening and washout, eligible patients were stratified by the baseline International Prostate Symptom Score (IPSS) and randomised (1:1:1) to receive FDC dutasteride 0.5 mg/tadalafil 5 mg (FDC 0.5/5 mg), dutasteride 0.5 mg, or tadalafil 5 mg for 48 weeks. The primary endpoint was the change in total IPSS from baseline to Week 48. Efficacy and safety were assessed at 4, 12, 24, 36, and 48 weeks. Results In total, 619 patients were analysed for efficacy. The least squares (LS) mean (standard error [se]) change in total IPSS at 48 weeks from baseline was -9.49 (0.37) for the FDC 0.5/5 mg group vs -4.40 (0.37) for dutasteride 0.5 mg group (LS mean difference [LSMD] -5.09, 95% confidence interval [CI] -6.13 to -4.50; P < 0.001), and -9.53 (0.36) for the FDC 0.5/5 mg group vs -4.24 (0.37) for tadalafil 5 mg group (LSMD -5.29, 95% CI -6.30 to -4.27; P < 0.001). The FDC 0.5/5 mg group demonstrated the most pronounced improvement in quality of life. Although the maximum urinary flow rate and post-void residual volume improved in all groups, differences were not statistically significant. In the comparison between the FDC 0.5/5 mg and dutasteride 0.5 mg groups, the LSMD (95% CI) of change from baseline to Week 48 in the international index of erectile function - erectile function (IIEF - EF) total score was 4.03 (2.35 to -5.71) (P < 0.05). Among the 655 patients analysed for safety, treatment-emergent adverse events occurred in 32.88% (FDC 0.5/5 mg) vs 21.20% (dutasteride 0.5 mg) and 26.48% (tadalafil 5 mg), with few serious adverse events observed. Conclusions The FDC 0.5/5 mg demonstrated superior efficacy, and an acceptable safety profile compared with dutasteride and tadalafil monotherapies in patients with BPH.

2026-04-01T00:00:00Z